Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $12

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $16 to $12.
byBenzinga Newsdesk
March 16, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $16 to $12.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts